Search the database for deliberate release of GM medicinal products
Displaying 1 - 3 of 3
|EU record number
|Company / Sponsor
|Only notified under the "contained use" procedure. Dossier submitted on 04/10/2018.
|A Phase 3, Randomized, Double-blind, Placebo-controlled study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1 + Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy
|Replication deficient lentiviral vector encoding NY-ESO-1 cancer testis antigen
|Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis
|Gene coding for the human interleukin-10 (hIL-10)
|Only notified under the "contained use" procedure. Dossier submitted on 09/06/1998.
|A phase II, multi-center, open label, randomized study to evaluate biodistribution and transmission, effectiveness and safety of two treatment regimens of Ad5CMV-p53 administered by intra-tumoral injections in 40 evaluable patients with advanced squamous